Innovision board meets May 25 to consider FY26 results

1 min read Updated on 20 May 2026, 04:53 PM

Reviewed by

Jubin VScanX News Team

AI Summary

Innovision Limited will hold a board meeting on May 25, 2026, to approve audited financial results for the quarter and fiscal year ending March 31, 2026. The trading window is closed until 48 hours after the results are declared.

*this image is generated using AI for illustrative purposes only.

Innovision Limited has announced that its board of directors will meet on Monday, May 25, 2026. The meeting has been convened pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015.

The primary agenda for the meeting is to consider and approve the audited standalone and consolidated financial results of the company for the quarter and financial year ended on March 31, 2026. Additionally, the board will discuss any other matters that may arise during the proceedings.

In compliance with the company’s code of conduct and the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of the company remains closed. This restriction applies to designated persons and their immediate relatives and has been in effect since March 23, 2026. The window will remain closed until the expiry of 48 hours after the declaration of the audited financial results.

Key Meeting Details

Detail	Information
Company Name	Innovision Limited
Meeting Date	May 25, 2026
Purpose	Consider Audited Standalone and Consolidated Financial Results
Period Ended	March 31, 2026
Trading Window Status	Closed until 48 hours post-result declaration

The company has requested the stock exchanges to take the intimation on record. Innovision Limited is listed on both the BSE Limited and the National Stock Exchange of India Limited.

How might Innovision Limited's FY2026 annual financial results compare to its previous year's performance, and what revenue growth trajectory can investors expect?

Will the board meeting on May 25, 2026 include any discussions on dividend declarations or capital allocation strategies for shareholders?

How could Innovision Limited's audited results influence its stock performance on BSE and NSE once the trading window reopens after the 48-hour restriction period?

IPO Fund Raising Overview

The company completed its Initial Public Offer on 23rd March 2026, raising gross proceeds of 2,550 Million from the fresh issue. Net proceeds from the offering stood at 2097.99 Million. CRISIL Ratings Limited has been appointed as the monitoring agency to oversee the utilization of these funds.

The key details of the fund-raising exercise are summarized below:

Parameter:	Details
Mode of Fund Raising:	Initial Public Offer
Date of Raising Funds:	23rd March 2026
Gross Proceeds (Fresh Issue):	2,550 Million
Net Proceeds:	2097.99 Million
Report Filed for Year Ended:	31st March 2026
Monitoring Agency:	CRISIL Ratings Limited
Deviation/Variation in Use of Funds:	No

Fund Utilization Against Original Objects

The company disclosed the utilization of IPO proceeds across three stated objects. As of the reporting period, funds have been fully deployed towards debt repayment, while working capital requirements and general corporate purposes remain pending utilization. The detailed breakdown is presented below:

Original Object:	Original Allocation	Fund Utilised	Deviation/Variation
Repayment or prepayment of borrowings:	510.00 Million	510.00 Million	N.A.
Funding Working Capital Requirements:	1,190.00 Million	0	N.A.
General Corporate Purposes:	397.99 Million	0*	N.A.

*Note: During the reported period, an amount of ₹118/- was utilized towards bank charges incurred in the Monitoring Agency account of the company maintained with Kotak Bank Limited.

Compliance and Regulatory Context

The filing confirms that there is no deviation or variation in the objects or purposes for which the funds were raised, no deviation in the amount of funds actually utilized as against what was originally disclosed, and no change in terms of any contract referred to in the fund-raising documents. The Audit Committee's comments and auditor remarks are not applicable, as no deviation has been reported.

The statement has been digitally signed and submitted by Jyoti Sachdeva, Company Secretary and Compliance Officer (M. No. A22176), on behalf of Innovision Limited.

When does Innovision Limited plan to deploy the remaining ₹1,587.99 Million allocated for working capital requirements and general corporate purposes, and what milestones will trigger this utilization?

How might the delay in deploying working capital funds impact Innovision Limited's operational growth and competitive positioning in the near term?

Will CRISIL Ratings Limited's ongoing monitoring of fund utilization influence Innovision Limited's credit rating or future borrowing costs as the remaining IPO proceeds are deployed?